Cargando…
Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma
BACKGROUND: In this retrospective study, we investigated the efficacy and safety of radioimmunotherapy with (90)Yttrium- ibritumomab tiuxetan ((90)Y-RIT) in 9 patients with recurrent follicular lymphoma (FL) who were treated in a consolidation setting after having achieved complete (CR) or partial r...
Autores principales: | Pisani, Francesco, Sciuto, Rosa, Dessanti, Maria Laura, Giannarelli, Diana, Kayal, Ramy, Rea, Sandra, Marchesi, Francesco, Marino, Mirella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482187/ https://www.ncbi.nlm.nih.gov/pubmed/26120498 http://dx.doi.org/10.1186/s40164-015-0012-3 |
Ejemplares similares
-
FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by (90)yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases
por: Pisani, Francesco, et al.
Publicado: (2011) -
90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years
por: Casadei, Beatrice, et al.
Publicado: (2016) -
Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
por: Lehnert, Martina, et al.
Publicado: (2009) -
Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma
por: Emmanouilides, Christos
Publicado: (2009) -
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
por: Mondello, Patrizia, et al.
Publicado: (2015)